NOVEL COMPOUNDS AND USES

Luke A.J. O'Neill; Rebecca Coll; Matthew A Cooper; Avril A B Robertson; Kate Schroder; Angus Murray Macleod; David John Miller

NOVEL COMPOUNDS AND USES

Luke A.J. O'Neill (Inventor), Rebecca Coll (Inventor), Matthew A Cooper (Inventor), Avril A B Robertson (Inventor), Kate Schroder (Inventor), Angus Murray Macleod (Inventor), David John Miller (Inventor)

School of Medicine, Dentistry and Biomedical Sciences

Research output: Patent

Abstract

The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

Original language	English
Patent number	PCT/IB2017/053059
Filing date	24/05/2017
Publication status	Published - 29 Nov 2018

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018215818

Cite this

@misc{66e8f3f9f4274d959a3ff7ee763c3c9a,

title = "NOVEL COMPOUNDS AND USES",

abstract = "The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.",

author = "O'Neill, {Luke A.J.} and Rebecca Coll and Cooper, {Matthew A} and Robertson, {Avril A B} and Kate Schroder and Macleod, {Angus Murray} and Miller, {David John}",

year = "2018",

month = nov,

day = "29",

language = "English",

type = "Patent",

note = "PCT/IB2017/053059",

}

TY - PAT

T1 - NOVEL COMPOUNDS AND USES

AU - O'Neill, Luke A.J.

AU - Coll, Rebecca

AU - Cooper, Matthew A

AU - Robertson, Avril A B

AU - Schroder, Kate

AU - Macleod, Angus Murray

AU - Miller, David John

PY - 2018/11/29

Y1 - 2018/11/29

N2 - The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

AB - The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

M3 - Patent

M1 - PCT/IB2017/053059

Y2 - 2017/05/24

ER -

NOVEL COMPOUNDS AND USES

Abstract

Access to Document

Fingerprint

Cite this